Skip to content
Search

Latest Stories

Britain to taste Tata Tetley’s Indian flavoured ethnic tea range 

INDIAN conglomerate owned Tetley tea will energise the Indian diaspora in the UK with a special ethnic dust tea.

The Tata Group-owned brand has announced the launch of its special ethnic range targeted at the diaspora population.


The latest product range will have three flavours - Masala, Cardamom and Ginger, already available in the south Asian country.

The speciality Indian flavours, aimed at the south Asian diaspora residing in the UK, as well as across Europe, are expected to address a gap in the market for authentic Indian "chai" tea bags, said owners of Britain’s tea brand Tata Global Beverages Ltd.

Adil Ahmad, President of the International Business at Tata Global Beverages Ltd, said: "This is the first time a mainstream tea brand is disrupting the tea category by offering an authentic desi (local) chai experience in a tea bag format."

Rahul Kale, the UK-based export consultant to Tata Global Beverages Ltd, said: "Unlike other Indian spiced teas and chai mixes, which are targeted mainly towards the mainstream tea consumers, Tetley ethnic range has specifically been blended and packed in India keeping the south Asian diaspora in mind…”

Tetley is among the world's largest tea businesses with a history of over 180 years.

The Indian business giant had acquired the brand nearly 10 years ago.

It has a brand presence in more than 40 countries around the globe.

More For You

pharmacy

The UK spends just 9 per cent of healthcare budgets on medicines while patients face growing access gaps.

iStock

UK calls for new pharmaceutical investment to strengthen life sciences

Highlights

  • UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
  • Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
  • Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.

Investment gap

Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.

Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.

Keep ReadingShow less